Theodore Laetsch
Children's Hospital of Philadelphia
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Theodore Laetsch as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:50 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT06458036 · Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)Children's Hospital of Philadelphia · recruiting · Differentiated Thyroid Cancer, Pediatric Cancer, Cancer · principal investigator
- Ph1NCT06156410 · Cabozantinib With Ifosfamide in Relapsed/Refractory SarcomasChildren's Hospital of Philadelphia · recruiting · Ewing Sarcoma, Osteosarcoma, Sarcomas · principal investigator
- Ph1/Ph2NCT05918640 · Lurbinectedin in FET-Fused TumorsChildren's Hospital of Philadelphia · recruiting · Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer · principal investigator
- N/ANCT05910307 · Synovial Sarcoma Registry / Biospecimen RepositoryChildren's Hospital of Philadelphia · recruiting · Synovial Sarcoma · principal investigator
- Ph2NCT05783323 · Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid CancerChildren's Hospital of Philadelphia · recruiting · Differentiated Thyroid Cancer, Pediatric Cancer, Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:50 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- PROMISE — Pediatric Rare-tumor Observational MultI-Source Evidence NetworkU01FD008977 · FDA · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2026 · $1,498,821 awarded in 2026Same name and institution; not confirmed by an ID
- Rare Tumor Clinical Research SpecialistR50CA305079 · NCI · CHILDREN'S HOSP OF PHILADELPHIA · fiscal years 2025 to 2026 · $197,518 awarded in 2026Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:50 UTC. The ranking covers the 200 most relevant of 27 PubMed records, and a shared surname and initials can bring in a namesake. All 27 on PubMed
- Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia.N Engl J Med · 20184,679 citationsRCR 163.2
- 2,232 citationsRCR 80.0
- Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.Lancet Oncol · 2020856 citationsRCR 36.6
- Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study.Lancet Oncol · 2018463 citationsRCR 15.8
- Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial.J Clin Oncol · 2023345 citationsRCR 28.7
- 279 citationsRCR 10.9
- Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma.Cancer Discov · 2021267 citationsRCR 14.2
- Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors.Neuro Oncol · 2022160 citationsRCR 10.6
- The use of neoadjuvant larotrectinib in the management of children with locally advanced TRK fusion sarcomas.Cancer · 2018114 citationsRCR 3.5
- Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.J Natl Cancer Inst · 201788 citationsRCR 2.4